✦ LIBER ✦

Drug Combinations: FDA in Earnest

Book ID: 109665819
Publisher: Nature Publishing Group
Year: 1969
Tongue: English
Weight: 148 KB
Volume: 221
Category: Article
ISSN: 0028-0836
DOI: 10.1038/221213a0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Drug promotion: FDA steps in

✍ Budiansky, Stephen 📂 Article 📅 1982 🏛 Nature Publishing Group 🌐 English ⚖ 328 KB

Use of Drug Combinations in Hypertension

✍ Doyle, A. E. 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 383 KB

FDA aims for neutral tone in drug-reject

FDA aims for neutral tone in drug-rejection letters

📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 229 KB

In vitro activity of nicotinamide/antile

In vitro activity of nicotinamide/antileishmanial drug combinations

✍ Elodie Gazanion; Baptiste Vergnes; Marie Seveno; Deborah Garcia; Bruno Oury; Kha 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 747 KB

Drug development in inflammatory bowel d

Drug development in inflammatory bowel disease: The role of the FDA

✍ Conor Lahiff; Sunanda Kane; Alan C. Moss 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB 👁 2 views

All medicinal compounds sold in the United States for inflammatory bowel disease (IBD) are regulated by the Food and Drug Administration (FDA) via a number of regulations dating back to 1906. The primary contemporary role of the FDA is in the assessment of safety and efficacy, and subsequent marketi

How the fda determines the “safety” of d

How the fda determines the “safety” of drugs: Are drugs used in obstetrics really “safe”?

✍ Doris Haire 📂 Article 📅 1982 🏛 Elsevier Science ⚖ 480 KB